Zithromax linked to cardiovascular death

A study published in the New England Journal of Medicine May 17, 2012 reports a small increase in cardiovascular deaths, and in the risk of death from any cause, in persons treated with a 5-day course of azithromycin (Zithromax) compared to persons treated with amoxicillin, ciprofloxacin, or no drug. FDA is reviewing the results from this study and will communicate any new information after the agency has completed its review.